BridgeMD
New treatment option for Melanoma
Official title A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT05538130
What this study is testing
What is PF-07799544?
PF-07799544 is an investigational medicine, given as a twice-daily pill taken by mouth, being studied as a potential treatment for melanoma.
Also referred to as ARRY-134.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 and older
You may be able to join if
- Phase 1b
- Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer)
- Measurable disease by RECIST version 1.1
- Evidence of a BRAF V600 mutation
- Prior therapy per tumor cohort
You likely can't join if
- Other active malignancy within 3 years
- Presence of leptomeningeal disease
- History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease
- Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
- Active gastrointestinal disease as defined per protocol
- History of interstitial lung disease as defined per protocol
See the full eligibility criteria
- Phase 1b
- Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer)
- Measurable disease by RECIST version 1.1
- Evidence of a BRAF V600 mutation
- Prior therapy per tumor cohort
- Adequate organ function per protocol Phase 1b
- Other active malignancy within 3 years
- Presence of leptomeningeal disease
- History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease
- Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
- Active gastrointestinal disease as defined per protocol
- History of interstitial lung disease as defined per protocol
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Fayetteville, Arkansas, United States
- Rogers, Arkansas, United States
- Springdale, Arkansas, United States
- Los Angeles, California, United States
- Pasadena, California, United States
- San Francisco, California, United States
- Santa Monica, California, United States
- Tampa, Florida, United States
- New Orleans, Louisiana, United States
- Boston, Massachusetts, United States
- Waltham, Massachusetts, United States
- Detroit, Michigan, United States
- Saint Louis Park, Minnesota, United States
- Saint Paul, Minnesota, United States
- Basking Ridge, New Jersey, United States
- Middletown, New Jersey, United States
- Montvale, New Jersey, United States
- Brewster, New York, United States
- Commack, New York, United States
+ 32 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Fayetteville, Arkansas, United States; Rogers, Arkansas, United States; Springdale, Arkansas, United States; Los Angeles, California, United States; Pasadena, California, United States and 46 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.